Lv Aixia, Tu Zengrong, Huang Yunhua, Lu Weiying, Xie Baoguo
Reproductive Center, The 940th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou, Gansu 730050, P.R. China.
Reproductive Center, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Oncol Lett. 2021 Jan;21(1):54. doi: 10.3892/ol.2020.12316. Epub 2020 Nov 18.
Exosomal microRNAs (miRs/miRNAs) have been reported to be associated with cervical cancer. The aim of the present study was to investigate circulating exosomal miRNA as a biomarker for cervical cancer diagnosis. In the present study, samples from 6 patients with cervical cancer and 6 healthy control subjects were retrieved for exosomal RNA-sequencing. The results revealed that a total of 39 miRNAs were differentially expressed between patients with cervical cancer and healthy controls (P<0.001; fold-change >2.0). Exosomal miR-125a-5p was further quantified in plasma from 60 subjects, which included 22 healthy individuals and 38 patients with cervical cancer. miR-16a-5p served as the reference miRNA for quantitative PCR analysis of exosomal miR-125a-5p in patients with cervical cancer and healthy individuals. The results revealed that exosomal miR-125a-5p expression levels in the patients with cervical cancer were significantly lower than those in the healthy controls (P<0.001). Receiver operating characteristic (ROC) curve analyses were performed and the results revealed that the level of plasma exosomal miR-125a-5p was a potential marker for differentiating between non-cervical cancer and cervical cancer, with an ROC area under the curve of 0.7129. At the cut-off value of 2.537 for miR-125a-5p, cervical cancer diagnostic sensitivities and specificities were 59.1 and 84.2%, respectively. The present study provides confirmation that exosomal miR-125a-5p could potentially serve as a biomarker for cervical cancer diagnosis. The present study involved only a small number of clinical samples; more samples are required to support the conclusions of the present study.
据报道，外泌体微小RNA（miRs/miRNAs）与宫颈癌有关。本研究的目的是探讨循环外泌体miRNA作为宫颈癌诊断生物标志物的可能性。在本研究中，收集了6例宫颈癌患者和6例健康对照者的样本进行外泌体RNA测序。结果显示，宫颈癌患者与健康对照者之间共有39种miRNA表达存在差异（P<0.001；变化倍数>2.0）。对60名受试者血浆中的外泌体miR-125a-5p进行了进一步定量分析，其中包括22名健康个体和38名宫颈癌患者。miR-16a-5p作为宫颈癌患者和健康个体中外泌体miR-125a-5p定量PCR分析的参照miRNA。结果显示，宫颈癌患者外泌体miR-125a-5p的表达水平显著低于健康对照者（P<0.001）。进行了受试者工作特征（ROC）曲线分析，结果显示血浆外泌体miR-125a-5p水平是区分非宫颈癌和宫颈癌的潜在标志物，曲线下面积为0.7129。当miR-125a-5p的截断值为2.537时，宫颈癌诊断的灵敏度和特异度分别为59.1%和84.2%。本研究证实外泌体miR-125a-5p有可能作为宫颈癌诊断的生物标志物。本研究仅涉及少量临床样本；需要更多样本以支持本研究的结论。
